Mr. Ron Nagar reports

TEMPRAMED SIGNS EXCLUSIVE DISTRIBUTION AGREEMENT WITH LEADING CONSUMER HEALTH DISTRIBUTOR IN ISRAEL

Tempramed Technologies Ltd. has signed a definitive exclusive commercial distribution agreement with Guri A.A.O. to market and sell Tempramed's full product line across the retail market in Israel.

This agreement marks a significant milestone in Tempramed's worldwide commercialization strategy as the company accelerates its pivot from a direct-to-consumer on-line model toward large-scale retail pharmacy networks and B2B (business-to-business) medical payers. This transition aligns with the company's long-term strategy to improve global access, reduce patient acquisition costs and integrate its temperature-control solutions directly into the standard-of-care for millions of patients requiring temperature-sensitive medications.

Guri is among the top five distributors in Israel's retail sector and brings more than 50 years of industry leadership. The company exclusively distributes a wide range of internationally recognized brands, including GSK/Haleon oral care products and Cargill's Truvia natural sweeteners, and maintains deep, long-standing relationships with 2,500 of Israel's largest supermarkets, pharmacy chains, HMOs (health maintenance organizations) and independent pharmacies.

By securing exclusive rights to Tempramed's VIVI line and upcoming temperature-sensitive medical storage products, Guri will play a central role in bringing Tempramed's solutions to a market known for early adoption of advanced medical technologies and strong consumer engagement in diabetes management and chronic care.

"Tempramed is an innovative, cutting-edge and revolutionary company that is transforming how temperature sensitive medication is stored. Tempramed has created a category of its own, with literally no competition in market. We know the demand for its product line is high, as we conducted comprehensive checks and consultations with professional opinion leaders, retailers and pharmacists, all of whom were amazed and impressed by Tempramed's product portfolio," said Oded Guri, owner and chief executive officer of Guri. "Retail executives have already expressed a strong willingness to start selling the products. I'm proud to be among the first distributors of Tempramed products in the global market, and am fully confident that this partnership will contribute to Guri's business growth and reputation, enriching our product portfolio and expanding into new categories."

The agreement with Guri represents the first of several new regional partnerships as Tempramed executes a global expansion program covering Europe, the Middle East, North America and Asia. With eight patents and regulatory approvals across major jurisdictions, Tempramed's products are positioned to meet growing demand from health systems and payors requiring regulated, compliant cold-chain solutions for injectables, biologics, fertility medications, GLP-1 therapies and insulin.

"As we expand globally, our focus is on embedding Tempramed's technology within the retail and clinical ecosystems where patients already receive care," said Ron Nagar, CEO of Tempramed. "Partnering with a top-tier distributor like Guri aligns perfectly with our pivot from a digital B2C model to pharmacy-led distribution and B2B payor channels. This is a major step in making temperature-safe medication storage the global standard, improving outcomes, reducing wastage and enhancing safety for patients who rely on temperature-sensitive therapies every single day."

Third quarter financial results

The company also announces that it has filed its interim financial statements for the three and nine months ended Sept. 30, 2025, and the management's discussion and analysis for the same period. Third quarter financial results can be found on the company's profile at SEDAR+.

Update on previously announced offering

The company is pleased to provide an update regarding its previously announced non-brokered private placement (see news release dated Oct. 21, 2025). The company confirms that it continues to advance the offering and is working toward closing, subject to customary closing conditions and regulatory approvals. The offering remains a priority as the company executes on its strategic initiatives, including the recently announced exclusive distribution partnership with Guri in Israel and its broader transition to pharmacy-led distribution channels.

About Tempramed Technologies Ltd.

Tempramed is a global leader in innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, Tempramed develops patented, U.S. Food and Drug Administration-registered (FDA), space-grade thermal insulation hassle-free devices that work 24/7 for years without charging or external power. With a proven product line, including VIVI Cap and VIVI Epi, and a smart technology platform on the horizon, Tempramed enables patients and health care providers to confidently manage temperature-sensitive medications anywhere, any time. With operations in North America, Europe and Asia, Tempramed is advancing the future of medication protection and adherence.

We seek Safe Harbor.